The Jewish General Hospital, known officially as the Sir Mortimer B. Davis Jewish General Hospital since 1978, is an acute-care teaching hospital in Montreal, Quebec, Canada. The hospital is affiliated with McGill University and has 637 beds, one of the most of a hospital site in Canada.

There are 637 beds in McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology.

During the past decade, McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 21 clinical trials were completed, i.e. on average, 91.3% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 7 clinical trials were completed. i.e. 350% of trials that started reached the finish line.

Out of the total clinical trials conducted in "McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology" #1 sponsor was "Hoffmann-La Roche" with 21 trials, followed by "Genentech, Inc." with 6 trials sponsored, "Sir Mortimer B. Davis - Jewish General Hospital" with 4 trials sponsored, "DePuy Orthopaedics" with 2 trials sponsored and "Adherex Technologies, Inc." with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology" #1 collaborator was "National Institute of Neurological Disorders and Stroke (NINDS)" with 2 trials as a collaborator, "Canadian Breast Cancer Research Alliance" with 1 trials as a collaborator, "Canadian Institutes of Health Research (CIHR)" with 1 trials as a collaborator, "Duke Clinical Research Institute" with 1 trials as a collaborator and "Fondazione Italiana Linfomi ONLUS" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology" are "Neoplasms" (5 trials), "Prostate Cancer" (4 trials), "Bladder Cancer" (3 trials), "Alzheimer's Disease" (2 trials) and "Avascular Necrosis" (2 trials). Many other conditions were trialed in "McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology" in a lesser frequency.

Most popular intervention types in "McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology" are "Drug" (39 trials), "Radiation" (3 trials), "Device" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (6 trials), "Placebo" (6 trials), "Docetaxel" (5 trials), "Rituximab" (5 trials) and "Obinutuzumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology" are 35 trials for "All" genders, 6 trials for "Male" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology". undefined are not yet recruiting, 6 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 31 completed trials in McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, 13 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".